Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
31. (WO2012030953) 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2012/030953 International Application No.: PCT/US2011/049955
Publication Date: 08.03.2012 International Filing Date: 31.08.2011
IPC:
A61K 31/00 (2006.01) ,A61K 31/55 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
Applicants:
ANDERSON, Christen, M. [US/US]; US (UsOnly)
SHANAHAN, William, R. [US/US]; US (UsOnly)
ARENA PHARMACEUTICALS, INC. [US/US]; 6166 Nancy Ridge Drive San Diego, California 92121, US (AllExceptUS)
Inventors:
ANDERSON, Christen, M.; US
SHANAHAN, William, R.; US
Agent:
DUFFIELD, Jonathan, J.; Arena Pharmaceuticals, Inc. 6166 Nancy Ridge Drve San Diego, California 92121, US
Priority Data:
61/402,56501.09.2010US
61/403,18510.09.2010US
Title (EN) 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL
(FR) AGONISTES DU RÉCEPTEUR 5-HT2C DANS TRAITEMENT DE TROUBLES AMÉLIORÉS PAR RÉDUCTION DU TAUX DE NORADRÉNALINE
Abstract:
(EN) Uses of 5-HT2C receptor agonists in the treatment of disorders ameliorated by reduction of an individual's norepinephrine level, wherein said disorders include but are not limited to hypernorepinephrinemia, cardiomyopathy, cardiac hypertrophy, cardiomyocyte hypertrophy in post-myocardial infarction remodeling, elevated heart rate, vasoconstriction, acute pulmonary vasoconstriction, hypertension, heart failure, cardiac dysfunction after stroke, cardiac arrhythmia, metabolic syndrome, abnormal lipid metabolism, hyperthermia, Cushing syndrome, pheochromocytoma, epilepsy, obstructive sleep apnea, insomnia, glaucoma, osteoarthritis, rheumatoid arthritis, and asthma.
(FR) L'invention concerne des utilisations des agonistes du récepteur 5-HT2C dans le traitement de troubles améliorés par une réduction du taux de noradrénaline d'un individu, lesdits troubles comprenant, sans s'y limiter, l'hypernoradrénalinémie, la cardiomyopathie, l'hypertrophie cardiaque, l'hypertrophie cardio-myocytaire dans le remodelage post-infarctus du myocarde, une fréquence cardiaque élevée, une vasoconstriction, la vasoconstriction pulmonaire aiguë, une hypertension, l'insuffisance cardiaque, un dysfonctionnement cardiaque après un accident vasculaire cérébral, l'arythmie cardiaque, le syndrome métabolique, un métabolisme lipidique anormal, l'hyperthermie, le syndrome de Cushing, un phéochromocytome, l'épilepsie, l'apnée du sommeil obstructive, l'insomnie, un glaucome, l'arthrose, la polyarthrite rhumatoïde et l'asthme.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)